Doç. Dr. Orhan Çelen

E5- O.Çelen, İ.Kahraman, E.Yıldırım, U.Berberoğlu. “Correlation of vascular endothelial growth factor with clinicopathological variables in colorectal cancer patients”, Neoplasma, 2004;51(4), 293-299.

1. RN Hussain, H Heimann, B Damato. Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. Melanoma Research, 2020;30(1):102-106.
2. D Wang, L Luo, W Chen, LZ Chen, et al.  Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncology Reports 2014;31(3):1199-1204. 
3. M Asem, AT Abbas, M Al-Hemaly,et al.  Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma. Life Science Journal,  2013;10(3):1975-1981
4. Sun, Y. W., et al. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res 2013;12: 1045-53.
5. Sanchez, B. C., et al. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. European Journal of Cancer 2010;46: 1580-1587.
6. Wang GY, Wang XS, Wang SH, et al. Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues. International Journal of Colorectal Disease 2008;23(7):675-682.
7.  Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. Journal Of Translational Medicine   2008;6(1).
8. Famulsiki W, Sulkowska M, Wincewics A, et al. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 2006;53(1):43-48.
9. Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patient with breast cancer. International Journal of Surgical Pathology 2006; 14(1):49-55.
10. Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Research 2006; 115(1):85-90.
11. Lin JD, Chao TC. Vascular endothelial growth factor in thyroid cancer. Cancer Biotherapy and Radiopharmaceuticals 2005;20(6):648-661.

E6- U.Berberoğlu, E.Yıldırım, O.Çelen. “Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer”, The International Journal of Biological Markers 2004;19(2):130-134.

1. WEICHHAUS, M. G., Molecular aspects of the link between obesity, insulin resistance and breast cancer. Available from OpenAIR@RGU. [online]. 2020 Available from: http://openair.rgu.ac.uk
2. MG Donovan, SN Wren, M Cenker, et al. Dietary fat and obesity as modulators of BC risk: Focus on DNA methylation. British journal of Pharmacology, 2020;  1– 20. https://doi.org/10.1111/bph.14891
3. U Naseema, GVS Rao, N Pazhanivel, P Sriram, et al.  Piperine and its novel nano form target tumor necrosis factor-α (TNF-α) signaling in mouse model of lung tumor. IJCS, 2019;7(6):1876-1878.
4. CE Felix, IF Ehigiator, CF Chinedum Pro-inflammatory cytokines (TNF-α and IL-1) in Nigerian women with breast cancer. Open Journal of Immunology, 2018;8:13-28.
5. K Thriveni, A Raju, G Ramaswamy, et al. Tumor necrosis factor: An inflammatory microen‑vironment marker in primary breast cancer patients.  Int J Mol ImmunoOncol 2018;3:24-27.
6. EM Domínguez-Martís, DG Mosteiro-Miguéns, et al.  Non-Platinum Metal Complexes as Potential Anti-Triple Negative Breast Cancer Agents. Crystals, 2018 ;8(10)369- .
7. S Kollabathina, G Sudhakar.  The Role of TNF-Alpha, Beta, XRCC1 and p53 Gene Predisposition in Cancers. Annual Research & Review inBiology, 2018;24(6):1-12. 
8. ZAP Wintrob, JP Hammel, T Khoury, et al. Insulin use, adipokine profiles and breast cancer prognosis. Cytokine, 2017;89:45-61.
9. B ZHUAN .ASSOCIATION OF GENE POLYMORPHISMS AND XPD EXPRESSION ON RISK OF NASOPHARYNGEAL CARCINOMA AND SURVIVAL AMONG …2017 - psasir.upm.edu.my
10. T Kashyap, C Argueta, A Aboukameel, et al. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget, 2016;7(48):78883-78895.
11. IA Gutiérrez-Hurtado, AM Puebla-Pérez, et al. Association between TNF-α-308G> A and-238G> A gene polymorphisms and TNF-α serum levels in Mexican colorectal cancer patients. Genetic and Molecular Research, 2016;15(2) gmr15028199.
12. P Raaschou, T Frisell, J Askling.  TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.  Annals of the rheumatic diseases, 2015;74(12):2137-2043.
13. D Vyas, N Lopez-Hisijos, S Gandhi, et al.  Doxorubicin-Hyaluronan conjugated super-paramagnetic iron oxide nanoparticles (DOX-HA-SPION) enhanced cytoplasmic uptake of doxorubicin and modulated. Journal of nanoscience and nanotechnology. 2015;15(9):6413-6422. 
14. LOWPIN YAN . Tumour-Conditioned Macrophages Up-Regulate Endothelial-Derived Fibronectin to Facilitate Lung Metastasis in Breast Cancer. 2015- cholarbank.nus.edu.sg
15. XL Zhou, W Fan, G Yang, MX Yu.  The clinical significance of PR, ER, NF-κB, and TNF-α in breast cancer. Disease markers, 2014 open accsess.
16. JA Cook.  Classical monocytes from patients with pancreatic ductal adenocarcinoma exhibit a significantly altered transcriptome profile compared with healthy volunteers. Queen Mary University of London Thesses. 2014.
17. P Raaschou. Anti-TNF therapy and malignancy in patients with rheumatoid arthritis: studies on cancer incidence, recurrence and survival. 2014: openarchive.ki.se
18. Raaschou, Pauline, et al. "TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study." Annals of the rheumatic diseases (2014): annrheumdis-2014.
19. da Rocha, Aline Franco, et al. Inhibitory effect of tumor necrosis factor α on gluconeogenesis in perfused rat liver. Molecular and cellular biochemistry 2013;375: 89-96.
20. Flores-Ramos, L. Gómez, et al. Association of the tumor necrosis factor-alpha− 308 G> A polymorphism with breast cancer in Mexican women. Genetics and Molecular Research  2013;121(4): 5680-5693.
21. To, Sarah Q., Kevin C. Knower, and Colin D. Clyne. Origins and Actions of Tumor Necrosis Factor α in Postmenopausal Breast Cancer. Journal of Interferon & Cytokine Research 2013;33(7): 335-345.
22. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacologica Sinica   2008;29(11):1275-1288.
23. Grim-Stieger M, Keilani M, Mader RM, et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate. Preliminary data of Viennese outpatint with metastatic cancer during palliative chemotherapy. European Journal of Cancer Care 2008;17:454-462.
24. Fagerholm R, Hofstetter B, Tommiska J, et al. NAD(P)H:Quinone oxidoreductase 1 NOO1 (star) 2 genotype (P187S) is astrong prognostic and predictive factor in breast cancer. Nature Genetics 2008;40:844-853.
25. Mills PJ, Ancoli-Israel S, Parker B, et al. Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behavior and Immunity 2008;22(1):98-104.
26. Premkumar VG, Yuvaraj S, Vijayasarathy K, et al.Serum cytokine levels of interleukin-1 beta,-6,-8,tumor necrosisfactor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic and Clinical Pharmacology and Toxicology 2007;100:387-391. 
27. Sirotkovic-Skerlev M, Cacev T, Kapitanovic S. Tumor necrosis Factor alpha and breast cancer. Periodicum Biologorum 2006;108:541-546.
28. Beresford M, Padhani AR, Goh V, et al. Imaging breast cancer response during neoadjuvant systemic therapy. Expert review of Anticancer Therapy 2005;5:893-905.

E7- O.Çelen, E.Yıldırım, U.Berberoğlu. “Factors influencing outcome of surgery for stage I rectal cancer”, Neoplasma 2004;51(6), 487-490 .

1. B Xu, L Yu, LZ Zhao, DW Ma Prognostic factors in the patients with T2N0M0 colorectal cancer. World journal of surgical oncology, 2016;14:76-.
2. Uribarrena A, Rafael, et al. Prognostic value of microvascular density in Dukes A and B (T1–T4, N0, M0) colorectal carcinomas." Gastroenterology research and practice 2009 (2009).
3. Uribarrena-Amezaga, R., et al. Prognostic value of lymph node micrometastasis in patients with colorectal cancer in Dukes stages A and B (T1-T4, N0, M0). Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 2010;102(3): 176-186.
4. Ptok H, Meyer F, Steinert R, et al. No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer - results of a multicenter observational study International Journal of Colorectal Disease   2007;22(7):749-756.

E8- E. Yıldırım, O. Çelen, K. Gülben and U. Berberoğlu. ”The surgical management of incidental gallbladder carcinoma”,  European Journal of Surgical Oncology 31(1),45-52 (2005).

1. JS Kim, SY Rho, HK Hwang , et al. A case of Wernicke's encephalopathy following complicated laparoscopic pylorus-preserving pancreaticoduodenectomy. Ann Hepatobiliary Pancreat Surg. 2019;23(3):295-299.   https://doi.org/10.14701/ahbps.2019.23.3.295. 
2. S Demiryas, O Akıncı, N Kepil, et al. Incidental Gallbladder Cancer after Laparoscopic Cholecystectomy for Cholelithiasis, and Factors Affecting the Prognosis: A Single-center Experience. Med Bull Haseki 2019;57:296-303
3. BH Kim, SH Kim, IS Song, et al. The appropriate surgical strategy for T1b gallbladder cancer incidentally diagnosed after a simple cholecystectomy. Ann Hepatobiliary Pancreat Surg. 2019;23(4):327-333.   https://doi.org/10.14701/ahbps.2019.23.4.327
4. N Köhn, J Maubach, R Warschkow, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB, 2018;20(11):1073-1081.
5. SG Barreto, A Dutt, B Sirohi,et al.  Gallbladder cancer: a journey of a thousand steps. Future Oncology, 2018;14(13):1299-1306.T Mahlobo. A review of the histopathological disease profile of gallbladder specimens after cholecystectomy. 2018 - wiredspace.wits.ac.za. https://hdl.handle.net/10539/25308
6. X Yang, J Chen, Z Wen, Y Ling  et al. Comparison of characteristics and survival between incidental and suspected gallbladder carcinoma. Int J Clin Exp Med, 2018; 11(4):3866-3872
7. SM Wrenn, PW Callas, W Abu-Jaish  Histopathological examination of specimen following cholecystectomy: are we accepting resect and discard? Surgical endoscopy, 2017;31(2): 586-593
8. M Sternby Eilard, L Lundgren, C Cahlin, et al.  Surgical treatment for gallbladder cancer–a systematic literature review. Scandinavian journal of Gastroenterology  2017;52(5): 505-514.
9. M Utsumi, H Aoki, T Kunitomo, et al.  Evaluation of surgical treatment for incidental gallbladder carcinoma diagnosed during or after laparoscopic cholecystectomy: single center results.  BMC Res Notes 2017;10:56. https://doi.org/10.1186/s13104-017-2387-1
10. SA Al-Namil, RS Manuel, NS Jumah, et al.  The Necessity for Routine Histopathological Examination of all Cholecystectomy Specimens. The Medical Journal of Basrah University, 2017; 35(2): 105-108. doi: 10.33762/mjbu.2017.134242
11. J Yamaguchi, Y Kaneoka, A Maeda,et al.  Benefit of extended radical surgery for incidental gallbladder carcinoma Surgery today, 2016;46(4):453-459.
12. M Goel, A Tamhankar, V Rangarajan, et al. Role of PET CT scan in redefining treatment of incidental gall bladder carcinoma. Journal of surgical oncology, 2016;113(6):652-658.
13. M Baig, M Guarino, N Petrelli. Report on demographics of gall bladder cancer in Delaware and retrospective review of treatment strategies for gallbladder cancer in a large community cancer center. Surgical oncology, 2016;25(2):86-91
14. Xu M., Meng H. (2016) Hepatectomy for Gallbladder Carcinoma. In: Yan L. (eds) Operative Techniques in Liver Resection. Springer, Dordrecht
15. SL Jee, KF Lim, K Raman, H Singh Squamous Cell Carcinoma of Gallbladder Masquerading as Ruptured Gallbladder Mucocele. Journal of Surgery & Transplantation Science, 2016;4(4):1033.
16. A Patel, W Sun Cholangiocarcinoma and Gallbladder Cancer. In: Sun W(eds) Multidisciplinary Management Of Gastrointestinal Cancers, 2016:pp423-456 . World Scientific
17. KS Choi, SB Choi, P Park,et al. Clinical characteristics of incidental or unsuspected gallbladder cancers diagnosed during or after cholecystectomy: a systematic review and meta-analysis. World Journal of Gastroenterology, 2015;21(4):1315-1323.
18. T Fujita.  Surgical strategy for incidental gallbladder cancer.  Journal of the American College of Surgeons, 2015;220(2):254-256
19. MA Kamble, AP Thawait, et al. Incidental gall bladder carcinoma in patients undergoing laparoscopic cholecystectomy. Journal of Evolution of of Medical and Dental Sciences, 2014;3(28): 7840-7852, DOI: 10.14260/jemds/2014/2982.
20. Yoon, Jong Hee, et al. "What is the Better Choice for T1b Gallbladder Cancer: Simple Versus Extended Cholecystectomy." World journal of surgery 38.12 (2014): 3222-3227.
21. Kai, Keita, Shinichi Aishima, and Kohji Miyazaki. "Gallbladder cancer: Clinical and pathological approach." World Journal of Clinical Cases: WJCC 2.10 (2014): 515.Gryko, 
22. M., et al. "Cancer of the gallbladder–own experience." Progress in Health Sciences 4.1 (2014): 153-157.
23. Salah, Berkane, and Abid Larbi. "Early Gallbladder Cancer: Clinical, Morphological, Therapeutic and Evolutionary Aspects." Surgical Science 4.11 (2013): 486.
24. Behari, Anu, and Vinay K. Kapoor. "Incidental Gall Bladder Cancer." Advances in surgery 47.1 (2013): 227-249.
25. Argon, Asuman, et al. "A Different Perspective on Macroscopic Sampling of Cholecystectomy Specimens." Korean journal of pathology 47.6 (2013): 519-525.
26. Kumar, Rakesh, et al. "Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma." Clinical nuclear medicine 37.5 (2012): 431-435.
27. Mazer, Laura M., et al. "Tumor characteristics and survival analysis of incidental versus suspected gallbladder carcinoma." Journal of Gastrointestinal Surgery 16.7 (2012): 1311-1317.
28. Wang, Jing-Han, et al. "Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer." Oncology reports 27.3 (2012): 775.
29. Lee, Seung Eun, et al. "Systematic review on the surgical treatment for T1 gallbladder cancer." World journal of gastroenterology: WJG 17.2 (2011): 174.
30.  TÜZÜNER, Acar, Esra ERDEN, and Kaan KARAYALÇIN. "Incidental gallbladder cancer diagnosed during or after laparoscopic cholecystectomy in members of the Turkish population with gallstone disease." Turk J Gastroenterol 22.5 (2011): 513-516.
31. Isambert, M., et al. "Incidentally-discovered gallbladder cancer: When, why and which reoperation?." Journal of visceral surgery 148.2 (2011): e77-e84.
32. Cho, Seong Yeon, et al. "Comparative analysis between clinical outcomes of primary radical resection and second completion radical resection for T2 gallbladder cancer: single-center experience." World journal of surgery 34.7 (2010): 1572-1578.
33. He, Xiao-Dong, et al. "Gender-specific prognostic markers of patients with gallbladder cancer after surgical resection." The American surgeon 76.11 (2010): 1269-1274.
34. Hueman, Matthew T., Charles M. Vollmer Jr, and Timothy M. Pawlik. "Evolving treatment strategies for gallbladder cancer." Annals of surgical oncology 16.8 (2009): 2101-2115.
35. Pilgrim, C., Val Usatoff, and Peter M. Evans. "A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour." European Journal of Surgical Oncology (EJSO) 35.9 (2009): 903-907.
36. Choi, Sae Byeol, et al. "Incidental gallbladder cancer diagnosed following laparoscopic cholecystectomy." World journal of surgery 33.12 (2009): 2657-2663.
37. Shibata, Kohei, et al. "Lymphatic invasion: an important prognostic factor for stages T1b–T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer." World journal of surgery 33.5 (2009): 1035-1041.
38. Reddy, Srinevas K., and Bryan M. Clary. "Surgical management of gallbladder cancer." Surgical oncology clinics of North America 18.2 (2009): 307-324.
39. De Aretxabala, Xabier, et al. "Early gallbladder cancer: is further treatment necessary?." Journal of surgical oncology 100.7 (2009): 589-593.
40. Pilgrim, Charles HC, Val Usatoff, and Peter Evans. "Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma." European Journal of Surgical Oncology (EJSO) 35.11 (2009): 1131-1136.
41. Abramson, Michael A., et al. "Radical resection for T1b gallbladder cancer: a decision analysis." HPB 11.8 (2009): 656-663.
42. Yeu, Kyung-jun, et al. "Should the extrahepatic bile duct be resected for T2 gallbladder cancer?." Journal of the Korean Surgical Society 77.2 (2009): 113-119.
43. Gourgiotis S, Kocher HM, Solaini L, et al. Gallbladder cancer. American Journal of Surgery 2008;96:252-264.
44. Zulke C, Schlitt HJ. Incidentalomas of the liver and gallbladder - Evaluation and therapeutic procedure  Chirurg   2007;78: 698-712.
45. Thomas MB.Biological characteristics of cancers in gallbladder and Biliary tract and targeted therapy. Critical Reviews in Oncology Hematology 2007;61:44-51.
46. Reid KM, Ramos-De la Medina A, Donohue JH.Diagnosis and surgical management of gallbladder cancer: A review.
    Journal of Gastroıntestınal Surgery 2007;11: 671-681.
47. Shirai Y, Wakai T, Hatakeyama K.Radical lymph node dissection for gallbladder cancer: Indications and limitations.Surgical Oncology Clinics of North America 2007;16: 221-+. 
48. Steinert R, Nestler G, Sagynaliev E, et al. Laparoscopic cholecystectomy and gallbladder cancer. Journal of Surgical  Oncology 2006;93:682-689. 
49. Misra MC, Gulera S. Management of cancer gallbladder found as a surprise on a resected gallbladder specimen. Journal of Surgical Oncology 2006;93:690-698.

E9- O. Çelen, E Yıldırım, N Özen, C Sonmez. “Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast” carcinoma. Neoplasma 2006;53,347-51.

1. Fleitas, T., et al. "VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer." Clinical and Translational Oncology 15.11 (2013): 897-902.
2. Reynés, Gaspar, et al. "Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma." Journal of neuro-oncology 102.1 (2011): 35-41.
3. Gökmen, Selma S., et al. "Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Sisplatin+ Etoposid Tedavisinin Serum Total ve Lipide Bağlı Sialik Asid Düzeylerine Etkisi." Türk Biyokimya Dergisi 35.3 (2010): 236.
4. Gokmen SS, Kazezoglu C, Tabakoglu E, et al. The importance of serum total and lipid-bound sialic acid as markers in patients with small cell and non-small cell lung carcinoma Trakya Ünıversitesi Tıp Fakultesi Dergisi 2007;24(2):101-108

E10- O.Çelen, E.Yıldırım, U.Berberoğlu. “Prognostıc impact of positive lymph node ratio in gastric carcinoma”, Journal of Surgical oncology 2007;96(2):95-101 . 

1. J Mansour, D Sagiv, E Alon, Y Talmi . Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma. The Journal of Laryngology & Otology, 2018;132(1):8-13. 
2. J Zhu, Z Xue, S Zhang, X Guo, at al.  Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis. International Journal of Surgery, 2018;576:76-83.
3. Y Hou, X Wang, J Chen.  Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer. World Journal of Surgical Oncology. 2018;16(1):198. DOI: 10.1186/s12957-018-1504-5.
4. K Bouliaris, G Rachiotis, A Diamantis, et al.  Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system. European Journal of Surgical Oncology, 2017;43(7):1350-1356.
5. Choi SY, Cho JK, Moon JH, Son YI. Metastatic Lymph Node Ratio of Central Neck Compartment Has Predictive Values for Locoregional Recurrence in Papillary Thyroid Microcarcinoma. Clin Exp Otorhinolaryngol. 2016;9(1):75–79. doi:10.21053/ceo.2016.9.1.75
6. YM Park, SG Wang, JC Lee, DH Shin, et al. Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: a prognostic factor of locoregional recurrence. Head & Neck 2016;38(S1):1172-1176.
7. P Kavaliauskas, R Maziukas, NE Samalavicius , et al. Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes.  Annals of Medicine and Surgery, 2016;6:36-41.
8. Attaallah W, Uprak K, Gunal O, Yegen C. Prognostic Impact of the Metastatic Lymph Node Ratio on Survival in Gastric Cancer. Indian J Surg Oncol. 2016;7(1):67–72. doi:10.1007/s13193-016-0490-8.
9. MZ Frasson, KS Kock, LF Monteiro, et al.  Number of lymph nodes dissected in colorectal cancer and probability of positive nodes, angiolymphatic/perineural invasion, and intracellular mucin in a referral service. Journal of Coloproctology,  2016;36(4):220-226.
10. C Rong, H Qingsheng, C Jianxin, et al.  Lymph node metastasis in early gastric cancer. Chinese medical Journal, 2014;127(3):560-567.
11. Smith, David D., Rebecca A. Nelson, and Roderich E. Schwarz. "A Comparison of Five Competing Lymph Node Staging Schemes in a Cohort of Resectable Gastric Cancer Patients." Annals of surgical oncology 21.3 (2014): 875-882.
12. Rosa, Fausto, et al. "Lymph node ratio for gastric cancer: useful instrument or just an expedient to retrieve fewer lymph nodes?." Annals of surgery 259.4 (2014): e65.
13. Ryu, In Sun, et al. "Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma." Annals of surgical oncology 21.1 (2014): 277-283.
14. Aurello, Paolo, et al. "Log Odds of Positive Lymph Nodes (LODDS): What Are Their Role in the Prognostic Assessment of Gastric Adenocarcinoma?." Journal of Gastrointestinal Surgery (2014): 1-7.
15. Zhang, Bao-yan, et al. "Evaluation of the prognostic value of the metastatic lymph node ratio for gastric cancer." The American Journal of Surgery 207.4 (2014): 555-565.
16. Lin, Dapeng, et al. "Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes." American journal of clinical oncology 36.4 (2013): 325-330.
17. Xu, Jia, et al. "Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection." World journal of gastroenterology: WJG 19.12 (2013): 1975.
18. Wang, Jiping, et al. "Comparison of a lymph node ratio–based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database." Annals of surgery 255.3 (2012): 478-485.
19. Lee, Sung Ryol, et al. "Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer." World journal of surgery 36.5 (2012): 1096-1101.
20. Lang, Brian Hung-Hin, et al. "Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection." Annals of surgical oncology 19.4 (2012): 1257-1263.
21. Deng, Jingyu, et al. "Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer." Tumor Biology 33.6 (2012): 2091-2098.
22. Wang, W., et al. "Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients." Annals of oncology (2011): mdq716.
23. Xiao, Long-Bin, et al. "Superiority of metastatic lymph node ratio to the 7th edition UICC N staging in gastric cancer." World journal of gastroenterology: WJG 17.46 (2011): 5123.
24. Petrelli, F., K. Borgonovo, and S. Barni. "The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature." European Journal of Surgical Oncology (EJSO) 37.10 (2011): 836-847.
25. Wenguang, Wu, et al. "Three-step method for lymphadenectomy in gastric cancer surgery: a single institution experience of 120 patients." Journal of the American College of Surgeons 212.2 (2011): 200-208.
26. Jacomo, Alfredo Luiz, et al. "Prognostic impact of the lymph node metastatic ratio on 5-year survival of patients with rectal cancer not submitted to preoperative chemoradiation." Journal of Coloproctology (Rio de Janeiro) 31.4 (2011): 311-324.
27. Sun, Zhe, et al. "Log odds of positive lymph nodes." Cancer 116.11 (2010): 2571-2580.
28. Lee, So-Young, et al. "Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes?." International journal of oncology 36.6 (2010): 1461-1467.
29. Maduekwe, Ugwuji N., et al. "New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma." Annals of surgical oncology 17.5 (2010): 1267-1277.
30. Bilici, Ahmet, et al. "Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer." Medical Oncology 27.3 (2010): 975-984.
31. Pedrazzani, Corrado, et al. "Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients." World journal of surgery 34.1 (2010): 85-91.
32. Kim, Jin-Soo, et al. "Increasing nodal ratio is a poor prognostic factor for survival in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study." Japanese journal of clinical oncology (2010): hyq215.
33. Xu, Da-zhi, et al. "Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes." Annals of surgical oncology 16.2 (2009): 319-326.
34. Sun, Z., et al. "The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients." Annals of oncology (2009): mdn707.
35. Macdonald, O. Kenneth, et al. "Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix." American journal of clinical oncology 32.4 (2009): 411-416.
36. Priolli, D. G., et al. "Metastatic lymph node ratio as an independent prognostic variable in colorectal cancer: study of 113 patients." Techniques in coloproctology 13.2 (2009): 113-121.
37. Kim, Chan-Young, and Doo-Hyun Yang. "Adjustment of N stages of gastric cancer by the ratio between the metastatic and examined lymph nodes." Annals of surgical oncology 16.7 (2009): 1868-1874.
38. Persiani, Roberto, et al. "Metastatic lymph node ratio: a new staging system for gastric cancer." World journal of surgery 33.10 (2009): 2106-2111.
39. Wang, Xi, et al. "Prognostic value of the ratio of metastatic lymph nodes in gastric cancer: an analysis based on a Chinese population." Journal of surgical oncology 99.6 (2009): 329-334.
40. Hagen, Jeffrey A. "Revisions in the Staging System for Esophageal." Esophageal Cancer: Principles and Practice (2009): 209.
41. Huang CM, Lin BJ, Lu HS, et al. Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus. World Journal of Surgery 2008;14:4383-4388. 
42. Nitti D, Mocellin S, Marchet A, et al. Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surgical Oncology Clinics of North America   2008;17: 467-+.
43. Wang X, Wang JJ, Wan F. A common misuse of stepwise regression in studies of ratio of metastatic lymph nodes for gastric cancer. Annals of Surgical Oncology   2008;15: 1805-1806. 
44. Zheng HC, Tsuneyama K, Takahashi H, et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. Journal of Cancer Research and Clinical Oncology 2008;134: 481-488.

E11- K. Gülben, U. Berberoğlu, O. Çelen, H.H.Mersin. “Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis”, Langenbecks Archives of Surgery 2008;333(1):25-29.

1. Q Zhang, Z Wang, X Meng, et al. [Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases. Asian journal of surgery, 2019;42(4):571-576.
2. R Reinke, JS Mathiesen, SR Larsen,et al. Incidental and Non-incidental Papillary Thyroid Microcarcinoma in Denmark 1996–2015: A national study on incidence, outcome and thoughts on active surveillance. Cancer Epidemiology,  2019;60:46-50.
3. A Rovira, IJ Nixon, R Simo.  Papillary microcarcinoma of the thyroid gland: current controversies and management. Current opinion in otolaryngology & head and Surgery, 2019 ;27(2):110-116.
4. Cayir, D., Kulah, B., Bozkurt, M. et al . Factors Influencing the Presence of Remnant Thyroid Tissue After Thyroidectomy for Differentiated Thyroid Carcinoma. Indian J Surg (2019). https://doi.org/10.1007/s12262-019-01889-1 
5. T Yang, SY Zheng, J Jiao, et al. Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis. Nuclear Medicine Communication,  2019;40(7):711-719. 
6. S Xu, W Liu, Z Zhang, et al. Routine prophylactic central neck dissection may not obviously reduce lateral neck recurrence for papillary thyroid microcarcinoma. ORL, 2019;81:73-81.
7. H Su, Y Li . Factors related to lymph node recurrence in patients with N1b papillary thyroid carcinoma after unilateral therapeutic modified radical neck dissection: A meta-analysis. Zentralbl Chir 2018; 143(04): 373-379  DOI: 10.1055/a-0652-5651
8. M Goran, T Pekmezovic, I Markovic, et L. Lymph node metastases in clinically N0 patients with papillary thyroid microcarcinomas-a single institution experience. JBUON 2017; 22(1): 224-231
9. Can N, Ozyilmaz F, Celik M, et al. Comparison of clinicopathological features in incidental and nonincidental papillary thyroid carcinomas in 308 patients. Polish Journal of Pathology. 2017;68(3):197-209. doi:10.5114/pjp.2017.71527.
10. Yi D, Song P, Huang T, Tang X, Sang J. A meta-analysis on the effect of operation modes on the recurrence of papillary thyroid microcarcinoma. Oncotarget. 2017;8(4):7148–7156. doi:10.18632/oncotarget.12698
11. M Kirnap, A Akdur, NG Kirnap, et al.  Thyroid Cancer Incidence and Clinicopathological Differences in Patients with End-Stage Renal Failure. J Endocrinol Research Studies. 2017;1(1):101-107
12. G Hu, W Zhu, W Yang,et al.  The effectiveness of radioactive iodine remnant ablation for papillary thyroid microcarcinoma: a systematic review and meta-analysis. World journal of surgery, 2016;40(1):100-109.
13. N Vorasubin, C Nguyen, M Wang . Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: A meta-analysis. Ear Nose Throat J, 2016; 95(2):73-77.
14. K Wang, G Wu. Intraoperative Neuromonitoring in Selective Neck Dissection for Thyroid Cancer: SND (IIa–Vb) with Wu Gaosong's Procedure. VideoEndocrinology, 2016 vol 3 No http://doi.org/10.1089/ve.2016.0082
15. A Jain, K Alam, V Maheshwari, et al. Papillary microcarcinoma in clinically benign thyroidology. Thyroid Research and Practice, 2016;13(1):15-18
16. Giordano, D., Frasoldati, A., Kasperbauer, J.L, et al.  Lateral neck recurrence from papillary thyroid carcinoma: Predictive factors and prognostic significance. The Laryngoscope, 2015;125: 2226-2231. doi:10.1002/lary.25094
17. X Yan, R Zeng, Z Ma, C Chen, et al.The utility of sentinel lymph node biopsy in papillary thyroid carcinoma with occult lymph nodes. PLoS One, 2015;10(6): e0129304.
18. J Joo, J Jin, ST Seo , et al. Recurrence in regional lymph nodes after total thyroidectomy and neck dissection in patients with papillary thyroid cancer.  Oral oncology, 2015;51(2):164-169.
19.  Y Xiang, K Lin, S Dong,et al.  Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China. Oncology Letters, 2015;10, 2559-2564. https://doi.org/10.3892/ol.2015.3544
20. Ozemir, I.A., Gurbuz, B., Bayraktar, B. et al. The effect of thyroid-stimulating hormone on tumor size in differentiated thyroid carcinoma.  Indian J Surg (2015) 77(Suppl 3): 967. https://doi.org/10.1007/s12262-014-1084-8.
21. Girardi, F.M., Barra, M.B. & Zettler, C.G. Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas: a retrospective study.  Pathol. Oncol. Res. 2015;21: 59. https://doi.org/10.1007/s12253-014- 9788-4 
22. Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R.M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S.J., Giles, T.E., Moss, L., Lewington, V., Newbold, K., Taylor, J.., Thakker, R.V.., Watkinson, J. and Williams, G.R. Guidelines for the management of thyroid cancer. Clin Endocrinol, 2014;81: 1-122. doi:10.1111/cen.12515
23. V Preda, M Korbonits, S Cudlip, et al.  Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. European journal of Endocrinology, 2014;171(5):659-666. 
24. SJ Diaz-Cano.  Multicentric Papillary Thyroid Carcinoma: Stratification for Treatment.  Journal of Cytology & Histology, 2014;5(4).
25. Mehanna, Hisham, et al. "Differences in the Recurrence and Mortality Outcomes Rates of Incidental and Nonincidental Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis of 21 329 Person-Years of Follow-Up." The Journal of Clinical Endocrinology & Metabolism (2014).
26. Brito, Juan P., Ian D. Hay, and John C. Morris. "Low risk papillary thyroid cancer." BMJ 348 (2014).
27. Girardi, Fábio Muradás, Marinez Bizarro Barra, and Cláudio Galleano Zettler. "Predictive Factors for Lymph Node Metastasis in Solitary Papillary Thyroid Carcinomas: A Retrospective Study." Pathology & Oncology Research (2014): 1-6.
28. Vinagre, João, et al. "Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature." Molecular Diagnostics 1 (2014): 10.
29. Nakamura, Masanori, et al. "E‑cadherin expression and cell proliferation in the primary tumor and metastatic lymph nodes of papillary thyroid microcarcinoma." Molecular and clinical oncology 2.2 (2014): 226-232.
30. Varshney, R., et al. "Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients." The Journal of Laryngology & Otology 128.10 (2014): 922-925.
31. Yang, Yinlong, et al. "Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma." Clinical endocrinology (2014).
32. Ardito, Guglielmo, et al. "Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy." Clinical nuclear medicine 38.1 (2013): 25-28.
33. Zhao, Qunzi, et al. "Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma." Annals of surgical oncology 20.3 (2013): 746-752.
34. Konturek, Aleksander, et al. "Prognostic factors in differentiated thyroid cancer—a 20-year surgical outcome study." Langenbeck's Archives of Surgery 397.5 (2012): 809-815.
35. Jee, Ye Seob. "First experiences with laparoscopic assisted distal gastrectomy: in the view of comparison with high volume centers." Journal of the Korean Surgical Society 83.3 (2012): 130-134.
36. Tanriover, Ozlem, et al. "Occult papillary thyroid carcinoma: prevalence at autopsy in Turkish people." European Journal of Cancer Prevention 20.4 (2011): 308-312.
37. Kamer, Erdinç, et al. "Tiroidin rastlantısal papiller mikrokarsinomları." Journal of Dialog in Endocrinology/Endokrinolide Diyalog Dergisi 8.3 (2011).
38. Sakorafas, George H., Dimitrios Sampanis, and Michael Safioleas. "Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties." Surgical oncology 19.2 (2010): e57-e70.
39. Zafon, Carles, et al. "Differences in the form of presentation between papillary microcarcinomas and papillary carcinomas of larger size." Journal of thyroid research 2011 (2010).
40. Gelmini, Roberta, et al. "Incidental thyroid carcinoma (ITC): a retrospective study in a series of 737 patients treated for benign disease." Ann Ital Chir 81.6 (2010): 421-7.
41. Lee, Nam Seop, et al. "Risk factors of lymph node metastasis in papillary thyroid microcarcinoma." Journal of the Korean Surgical Society 78.2 (2010): 82-86.
42. Kim, Ju-Yeon, et al. "Clinical characteristics and prognosis of multifocal papillary thyroid carcinoma." Journal of the Korean Surgical Society 79.6 (2010): 442-446.
43. Mercante, Giuseppe, et al. "Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients." Thyroid 19.7 (2009): 707-716.
44. Chung, Yoo Seung, et al. "Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection." Thyroid 19.3 (2009): 241-246.
45. Gül, Kamile, et al. "Comparison of Papillary Thyroid Microcarcinoma and Carcinoma." Turkish Journal of Endocrinology & Metabolism 13.3 (2009).
46.  Pakdaman MN, Rochon L, Gologan O, et al.Incidence and histopathological behavior of papillary microcarcinomas: Study of 429 cases. Otolaryngology-Head and Neck Surgery   2008;139:718-722. 
47. Roh JL, Kim JM, Park. Central cervical nodal metastasis from papillary thyroid microcarcinoma: Pattern and factors predictive of nodal metastasis. Annals of Surgical Oncology   2008;15:2482-2486.

A. Uluslararası hakemli dergilerde yayımlanan makaleler

A1. F.Buruk, U. Berberoğlu, I.Pak, E.Aksaz , O.Çelen. “Gastric cancer and Helicobacter pylori infection”, British Journal of Surgery, 80,378-379 (1993).

A2. K.Özgen, U.Berberoğlu, M.Altınok, E.Özdemir , O.Çelen. “Reconstruction of full-thickness cheek defects using platysma myocutaneous flaps”, European Journal of Plastic Surgery, 16,208-211 (1993).

A3. O.Çelen, M.J.O'Brien, J.C.Melby, R.M.Beazley. “Factors Influencing Outcome of Surgery for Primary Aldosteronism”, Archives of Surgery, 131,646-650 (1996).

A4. A.Özlük, E.Yıldırım, S.Oral, O.Çelen, U.Berberoğlu. “Carcinomas of the thyroid and breast associated with Pendred's Syndrome: Report of a case”, Surgery Today, 28,673-674 (1998).

A5. E.Yıldırım, O.Çelen, U.Berberoğlu. “The Turkish experience with curative gastrectomies for gastric carcinoma: Is D2 dissection worthwhile?”, Journal of the American College of Surgeons, 192,25-37 (2001).

A6. H.Altınyollar, U.Berberoğlu, O.Çelen. “Lymphatic mapping and sentinel lymph node biopsy in squamous cell carcinoma of the lower lip”, European Journal of Surgical Oncology, 28,72-74 (2002).

A7. O.Çelen, E.Yıldırım, K.Gülben, U.Berberoğlu. “Prediction of survival in gastric carcinoma related to lymph node grading by the new American Joint Committee on Cancer/Union International Contre le Cancer System or the Japanese System”, European Journal of Surgery, Suppl 588,33-39 (2002).

A8. O.Çelen, İ.Kahraman, E.Yıldırım, U.Berberoğlu. “Correlation of vascular endothelial growth factor with clinicopathological variables in colorectal cancer patients”, Neoplasma,51(4), 293-299 (2004).

A9. U.Berberoğlu, E.Yıldırım, O.Çelen. “Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer”, The International Journal of Biological Markers 19(2),130-134 (2004).

A10. O.Çelen, E.Yıldırım, U.Berberoğlu. “Factors ,influencing outcome of surgery for stage I rectal cancer”, Neoplasma 51(6), 487-490 (2004).

A11. E. Yıldırım, O. Çelen, K. Gülben and U. Berberoğlu. ”The surgical management of incidental gallbladder carcinoma”,  European Journal of Surgical Oncology 31(1),45-52 (2005).

A12. O.Çelen, E.Yıldırım, U.Berberoğlu. Prevention of wound edge necrosis by local application of  dimethylsulfoxide. Acta Chirurgica Belgica, 105,287-290 (2005).

A13. O. Çelen, E Yıldırım, N Özen, C Sonmez. “Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast” carcinoma. Neoplasma 53,347-51 (2006).

A14- O.Çelen, E.Yıldırım, U.Berberoğlu. “Prognostıc impact of positive lymph node ratio in gastric carcinoma”, Journal of Surgical oncology ;96(2):95-101. (2007). 

A15- Kaptan Gülben, Uğur Berberoğlu, Orhan Çelen, H.Hakan Mersin. Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis. Langenbecks Archives of Surgery 333(1):25-29 (2008).

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler :

B1- O.Çelen, U.Berberoğlu, E.Eroğlu, S.Çamlıbel. “Complications related to port-catheter systems in regional chemotherapy”, VI. International Conference on Regional Cancer Treatment. Wiesbaden, July 12-14,1993.(Poster)

B2- M.Berberoğlu, N.Kurt, O.Çelen, E.Gündoğdu, F.Gözübüyük. “A new laparoscopic maneuver resembling the Pringle's”, 1999 Scientific Session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), San Antonio, Texas, USA, March 24-27,1999.(Poster) 

B3-  E Yıldırım, U, Berberoğlu, O. Çelen, E.Semerci, S.Kalkan. The effect of topical dimethyl sulfoxide on surgical flaps. European Cancer Conference (ECCO 10), Viana, September 12-16 1999. (Poster)
B4- E.Yıldırım, O.Çelen, K.Gülben, U.Berberoğlu. Is the AJCC/UICC Staging system for gastric carcinoma more valid than the Japanese system? Eurosurgery 2000. İstanbul, 20-24 June 2000. (Sözel)

C. Ulusal hakemli dergilerde yayımlanan makaleler :

C1. K.Bakır, O.Çelen, U.Berberoğlu, T.Gürkale, N.Kapucuoğlu. “Memenin primer osteosarkomu”, Türk Patoloji Dergisi, 10, 40-42 (1994).

C2. H.Altınyollar, U.Berberoğlu, O.Çelen, A.Özlük. “Meme kanserinde kemik metastazı ile visseral organ tutulumu arasındaki ilişki”, Türk Onkoloji Dergisi, 9, 36-37 (1994).

C3. E.Yıldırım, A.Özlük, O.Çelen, U.Berberoğlu. “Gastrointestinal lenfomalar”, Acta Oncologica Turcica, 28, 101-104 (1995).

C4. E.Yıldırım, T.Çelen, O.Çelen, U.Berberoğlu. “Üst ekstremitenin malign tümörlerinin tedavisinde skapulotorasik amputasyon”, Acta Oncologica Turcica, 28, 116-117 (1995).

C5. A.Özlük, O.Çelen, E.Yıldırım, U.Berberoğlu. “Duktal Ektazi: 218 olgunun klinikopatolojik değerlendirilmesi”, Acta Oncologica Turcica, 29, 34-35 (1996).

C6. H.Altınyollar, K.Gülben, O.Çelen, E.Yıldırım, U.Berberoğlu. “İnce barsağın malign tümörleri”, Acta Oncologica Turcica, 30, 36-37 (1997).

C7. E.Yıldırım, O.Çelen, T.Dalgıç, H.Altınyollar, S.Çamlıbel, U.Berberoğlu. “Primer ve metastatik karaciğer tümörlerinde intraarteriyel kemoterapi”, Ulusal Cerrahi Dergisi,    14, 277-283 (1998).

C8 O.Çelen, E.Yıldırım, K.Gülben, H.Altınyollar, S.Çamlıbel,U.Berberoğlu. “Hepatosellüler karsinomlu 83 olguda tedavi yöntemlerinin değerlendirilmesi”, Acta Oncologica Turcica, 31, 63-65 (1998).

C9. E.Yıldırım, S.Sancaktar, O. Aktepe,  O.Çelen, U.Berberoğlu. “Bacterial translocation after extended liver resection”, Acta Oncologica Turcica, 32, 7-12 (1999).

C10. O.Çelen, H.Altınyollar, U.Berberoğlu. “Baş boyun malign melanomlarında süperfisial parotidektomi ve preaurikuler lenf nodu diseksiyonu”,  Acta Oncologica Turcica, 32, 7-12, (1999).

C11. M. Doğan, S.Oğuz, O.Çelen. “Yüksek enerjili ateşli silahlarla meydana gelen ekstremite yaralanmaları”, Ulusal Travma Dergisi, 6, 231-33 (2000).

C12. O.Çelen, S.Oğuz, M. Doğan. “Karına Yönelik ateşli silah yaralanmaları: 164 Olgunun retrospektif analizi”, Ulusal Travma Dergisi, 7, 258-61(2001).

C13. O.Çelen, E.Semerci, U.Berberoğlu. “Palpe edilemiyen meme lezyonlarında tel lokalizasyon eşliğinde biyopsi”, Acta Oncologica Turcica, 34, 46-50 (2001).

C14. E.Semerci, O.Çelen, U.Berberoğlu. “Deneysel akut pankreatitte kolesistokinin antagonistinin etkileri”, Ulusal Cerrahi Dergisi, 17, 333-38 (2001).

C15. O.Çelen, T.Dalgıç, U.Berberoğlu. “Deneysel peritonit modelinde granülosit koloni stimüle edici faktörün tümör nekrosis faktör alfa ve prognoz üzerine etkisi”, Ulusal Cerrahi Dergisi, 19, 181-187 (2003).

C16. O.Çelen. “ Meme başı akıntıları”, Ankara Cerrahi Dergisi, 7(4),128-134 (2005).

C17. H.Altınyollar, U.Berberoğlu, K.Gülben, O.Çelen. “Meme kanserinin infraklavikular metastazlarının prognostik parametrelerle ilişkisi”, Gazi Tıp Dergisi, 18(1), 18-21 (2007). 

D. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

D1. H.Altınyollar, U.Berberoğlu, O.Çelen, A.Özlük. “Meme kanserinde kemik metastazı ile visseral organ tutulumu arasındaki ilişki”, X. Ulusal Kanser Kongresi, The Marmara, İstanbul,3-7 Mayıs 1993.(Sözel)

D2. E.Yıldırım, A.Özlük, O.Çelen, U.Berberoğlu. “Gastrointestinal lenfomalar”, XI. Ulusal Kanser Kongresi, Antalya, Haziran 1995. (Poster)

D3. E.Yıldırım, T.Çelen, O.Çelen, U.Berberoğlu. “Üst ekstremitenin malign tümörlerinin tedavisinde skapulotorasik amputasyon”, XI. Ulusal Kanser Kongresi, Antalya, Haziran 1995. (Poster)

D4. O.Çelen, E.Yıldırım, A.Özlük, U.Berberoğlu. “İnflamatuar meme karsinomu”, 2. Ulusal Meme Hastalıkları Kongresi, İstanbul, 19-21 Ekim 1995. (Poster)

D5. A.Özlük, O.Çelen, E.Yıldırım, U.Berberoğlu. “Duktal Ektazi: 218 olgunun klinikopatolojik değerlendirilmesi”, 2. Ulusal Meme Hastalıkları Kongresi, İstanbul, 19-21 Ekim 1995. (Poster)

D6. O.Çelen, E.Yıldırım, U.Berberoğlu. “Mide kanserinde genişletilmiş lenfnodu diseksiyonunun yeri”, XII. Ulusal Kanser Kongresi, Belek, Antalya, 23-26 Nisan 1997 (Poster).

D7. O.Çelen, H.Altınyollar, U.Berberoğlu. “Baş boyun malign melanomlarında süperfisial parotidektomi ve preaurikuler lenf nodu diseksiyonu”,  XII. Ulusal Kanser Kongresi, Belek, Antalya, 23-26 Nisan 1997. (Poster)

D8. E.Yıldırım, O.Çelen, T.Dalgıç, H.Altınyollar, S.Çamlıbel, U.Berberoğlu. “Primer ve metastatik karaciğer tümörlerinde intraarteriyel kemoterapi”, Hepato-Pankreato-Bilier Bilimler Kongresi, Efes Kongre Merkezi, İzmir. 1-4 Kasım 1997. (Sözel)

D9. O.Çelen, E.Yıldırım, K.Gülben, H.Altınyollar, S.Çamlıbel, U.Berberoğlu. “Hepatosellüler karsinomlu 83 olguda tedavi yöntemlerinin değerlendirilmesi”, Hepato-Pankreato-Bilier Bilimler Kongresi, Efes Kongre Merkezi, İzmir. 1-4 Kasım 1997. (Sözel)

D10. E.Yıldırım, O.Çelen, U.Berberoğlu. “Malign melanomada popliteal disseksiyon”, Ulusal Cerrahi Kongresi'98, Efes Kongre Merkezi, İzmir, 6-10 Mayıs 1998.( Poster)

D11. H.Altınyollar, K.Gülben, O.Çelen, E.Yıldırım, U.Berberoğlu. “İnce barsağın malign tümörleri”, Ulusal Cerrahi Kongresi'98, Efes Kongre Merkezi, İzmir, 6-10 Mayıs 1998. (Poster)

D12. O.Çelen, E.Semerci, B.Arıbaş, G.Dingil, L.Kuşcu, U.Berberoğlu. “Palpe edilemiyen meme lezyonlarında tel lokalizasyon eşliğinde biyopsi”, Ulusal Cerrahi Kongresi'98, Efes Kongre Merkezi, İzmir, 6-10 Mayıs 1998.(Sözel)

D13. M.Berberoğlu, M.Özer, O.N.Dilek, M.Özmen, A.Yücel, O.Çelen. “Laparoskopik cerrahi temel ve ileri Eğitimde 3 yıllık kurs ve uygulama sonuçları”, Ulusal Cerrahi Kongresi'98, Efes Kongre Merkezi, İzmir, 6-10 Mayıs 1998.(Sözel)

D14. M.Berberoğlu, M.Özer, M.Özmen, O.N.Dilek, O.Çelen. “Yoğun preoperative eğitim ile bastırılmış laparoskopik öğrenim eğrisi”, Ulusal Cerrahi Kongresi'98, Efes Kongre Merkezi, İzmir, 6-10 Mayıs 1998.(Sözel)

D15. O.Çelen, S.Oğuz, H.Özberrak, M. Doğan. “Karına Yönelik ateşli silah yaralanmaları: 164 Olgunun retrospektif analizi”, 3. Ulusal Travma ve Acil Cerrahi Kongresi, Antalya  31 Ağustos-04 Eylül 1999. (Sözel)

D16. M. Doğan, S.Oğuz, O.Çelen, H.Özberrak, “Yüksek enerjili ateşli silahlarla meydana gelen ekstremite yaralanmaları”, 3. Ulusal Travma ve Acil Cerrahi Kongresi, Antalya  31 Ağustos-04 Eylül 1999. (Sözel)

D17. H.Özberrak, S.Oğuz, O.Çelen, M.Doğan. “Uzun namlulu silah ve parça tesirli bomba ile meydana gelen damar yaralanmalarına yaklaşım”, 3. Ulusal Travma ve Acil Cerrahi Kongresi, Antalya  31 Ağustos-04 Eylül 1999. (Sözel)

D18. O.Çelen, E.Yıldırım, C.Aygün, U.Berberoğlu. “Evre I rektum karsinomunda prognostik faktörler”, I. Ulusal Cerrahi Onkoloji Kongresi, Antalya, 26-28 Ekim 2000. (Sözel)

D19. E.Yıldırım, O.Çelen, K.Gülben, U.Berberoğlu. “Mide karsinomunda genç yaşın prognostik önemi”, I. Ulusal Cerrahi Onkoloji Kongresi, Antalya, 26-28 Ekim 2000. (Sözel)

D20. O.Çelen, E.Yıldırım, K.Gülben, U.Berberoğlu. “Diferansiye tiroid karsinomlu olgularda prognostik skorlama sistemlerinin değeri”, XIV. Ulusal Kanser Kongresi,2001, İstanbul, 30 Nisan-4 Mayıs 2001. (Sözel)

D21. O.Çelen, İ.Kahraman, E.Yıldırım, U.Berberoğlu. “Malign melanoma: 28 yıllık deneyim”, XIV. Ulusal Kanser Kongresi,2001, İstanbul, 30 Nisan-4 Mayıs 2001. (Poster)

D22. O.Çelen, S.Kalkan, U.Berberoğlu. “Mide kanserinde radikal cerrahinin serum interlökin 10 düzeyine etkisi”, Ulusal Cerrahi Kongresi,2002, Kemer, Antalya, 15-19 Mayıs 2002.(Sözel).

D23. O.Çelen, U.Berberoğlu. “Neoadjuvan kemoterapiye tam aksiller yanıt ve klinik önemi”, VII. Ulusal Meme Hastalıkları Kongresi, Kemer, Antalya, 16-19 Ekim 2003.(Sözel).

D24. U.Berberoğlu, E.Yıldırım, O.Çelen. “Lokal ileri meme kanserinde neoadjuvan kemoterapiye yanıtın serum TNF-α düzeyi ile korelasyonu”, VII. Ulusal Meme Hastalıkları Kongresi, Kemer, Antalya, 16-19 Ekim 2003.(Sözel).

D25. O.Çelen, A.Cengiz, U.Berberoğlu. “T1 meme kanserli olgularda aksiller lenf nodu pozitifliğine etki eden faktörler”, VIII. Ulusal Meme Hastalıkları Kongresi, İstanbul, 21-24 Eylül 2005.(Sözel).

D26. O. Çelen, E. Yıldırım, U. Berberoğlu. Mide kanserinde lenf nodu tutulum oranının prognostik önemi . Ulusal Cerrahi Kongresi, 24-28 Mayıs,Antalya,2006 (Sözel).

D27. K.Gülben, U. Berberoğlu, O. Çelen. “Tiroid papiller mikrokarsinomunda lenf nodu metastazını etkileyen faktörler.” Ulusal Cerrahi Kongresi, 24-28 Mayıs,Antalya,2006 (Sözel).

D28. K.Gülben, O. Çelen, U.Berberoğlu. Sitolojik olarak kanıtlanmış aksiller lenf nodu metastazında neoadjuvan kemoterapiye tam yanıtın prognostik önemi. 9. Ulusal MemeHastalıkları Kongresi, 5-9 Eylül, Ankara, 2007

E. Atıf yapılan yayınlar ve yapılan atıflar:

E1- F.Buruk, U. Berberoğlu, I.Pak, E.Aksaz , O.Çelen. Gastric cancer and Helicobacter

 pylori infection. British Journal of Surgery 1993;80:378-379.

1. H Ohyama, D Yoshimura, Y Hirotsu, et al.  Rapidly  declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori BMC Gasroenterology 2019, 19:178| 

2. Lucena RB, Rissi DR, Queiroz DM et al. Infiltrative gastric adenocarcinoma in chinchilla. J Vet Diagn Invest 2012 Jul;24(4):797-800

3. Lima VP, Silva-Fernandes IJL, Alves MKS, et al. Prevalence of Helicobacter pylori genotypes (vacA, cagA, cagE and virB11) in gastric cancer in Brazilian's patients: An association with histopathological parameters. Cancer Epidemiology 2011; 35: 32-37.

4. VP Lima, MAP Lima, MVP Ferreira, MAP Barros .The relationship between Helicobacter pylori genes cagE and virB11 and gastric cancer. Int. J. Infectious Disease 2010;14(7):613-617

5. Lima VP, de Lima MAP, Andre AR, et al. H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: Correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression. World Journal of Gastroenterology   2008;14(6):884-891

6.  Rocco A, Nardone G. Diet, H pylori infection and gastric cancer: Evidence and controversies. World Journal of Gastroenterology   2007;13(21):2901-2912. 

7. Hamaguchi K, Ogawa K, Katsube T, Konno S, Aiba M. Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residuel stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residuel stomach before and after Helicobacter pylori eradication. Langenbecks Archives of Surgery 2004;389:83-91.

8. Atalay C, Atalay G, Altınok M. Serum Helicobacter pylori IgG and IgA levels in patients with gastric cancer. Neoplasma 2003;50:185-190.

9. Cho HJ, Kim JY, Yoo J, Lee SS. Gastric carcinoma with lymphoid stroma- Incidence of EBV and Helicobacter pylori infection. Applied Immunohistochemistry & Molecular Morphology 2003;11:149-152.

10. Kyrlagkitsis I, Karamanolis DG. Premalignant lesions and conditions for gastric adenocarcinoma: Diagnosis, management and surveillance guidelines. Hepato-Gastroenterology 2003;50:592-600.

11. Katsube T, Ogawa K, Hamaguchi K, Murayama M, Konnno S, Shimakawa T, Naritaka Y, Yagawa H, Kajiwara T, Aiba M. Prevalence of Helicobacter pylori in the residual stomach after gastrectomy for gastric cancer. Hepato-Gastroenterology 2002;49:128-132.

12. Kath R, Fiehler J, Schneider CP, Hoffken K. Gastric cancer in very young adults: apropos four patients and a review of the literature. Journal of Cancer Research and Clinical Oncology 2000;126:233-237.

13. Ashley SW, Evoy D, Daly JM. Stomach In: Schwartz SI, ed. Principles of Surgery 7th ed. McGraw Hill; 1999:1181-1215. 

14. Jonkers D, Houben P, Hameeteman W, Stobberingh E, de Bruine A, Arends JW, Biemond I, Lundqvist G, Stockbrugger R. Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative. Italian Journal of Gastroenterology and Hepatology 1999;31:836-841.

15. Tabata H, Fuchigami T, Kobayashi H, Sakai Y, Nakanishi M, Tomioka K,  Nakamura S, Fujishima M. Helicobacter pylori and mucosal atrophy in patients with gastric cancer - A special study regarding the methods for detecting Helicobacter pylori. Digestive Diseases and Sciences 1999;44:2027-2034.

16. Eslick GD, Lim LLY, Byles JE, Xia HHX, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis. American Journal of Gastroenterology 1999;94:2373-2379.

17. Nyren O. Is Helicobacter pylori really the cause of gastric cancer?  Seminars In Cancer Biology 1998;8:275-283.

18. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian Gerbils. Gastroenterology 1998;115:642-648.

19. Enomoto H, Watanabe H, Nishikura K, Umezawa H, Asakura H. Topographic distribution of Helicobacter pylori in the resected stomach. European Journal of Gastroenterology & Hepatology 1998;10:473-478.

20. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179.

21. Borch K, Sjostedt C, Hannestad U, Soderholm JD, Franzen L, Mardh S.Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability. Digestive Diseases and Sciences 1998;43:749-753.

22. Iseki K, Tatsuta M, Iishi H, Baba M, Ishiguro S. Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Gut 1998;42:20-23.

23. Wu MS, Yang KC, Shun CT, Hsiao TJ, Lin CC, Wang HP, Chuang SM,  Lee WJ, Lin JT. Distinct clinicopathologic characteristics of diffuse- and intestinal-type gastric cancer in Taiwan. Journal of Clinical Gastroenterology 1997;25:646-649.

24. McFarlane GA, Munro A. Helicobacter pylori and gastric cancer. British Journal of Surgery 1997;84:1190-1199.

25. Wu MS, Chen SY, Shun CT, Lee WJ, Wang HP, Wang TH, Chen CJ, Lin JT. Increased prevalence of Helicobacter pylori infection among patients affected with intestinal-type gastric cancer at non-cardiac locations. Journal of Gastroenterology and Hepatology 1997;12:425-428.

26. MartindeArgila C, Boixeda D, Redondo C, Alvarez I, Gisbert JP, Plaza AG, Canton R. Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scandinavian Journal of Gastroenterology 1997;32:303-307.

27. Nagahata Y, Kawakita N, Azumi Y, Numata N, Yano M, Saitoh Y. Etiological involvement of Helicobacter pylori in ''reflux'' gastritis after gastrectomy. American Journal of Gastroenterology 1996;91:2130-2134.

28. McGuigan JE. Helicobacter pylori: The versatile pathogen. Digestive Diseases 1996;14:289-303.

29. Kokkola A, Valle J, Haapiainen R, Sipponen P, Kivilaakso E, Puolakkainen P. Helicobacter pylori infection in young patients with gastric carcinoma. Scandinavian Journal of Gastroenterology 1996;31:643-647.

30. Wu CW, Wu TC, Chang YR, Tsay SH, Yin SJ, Lui WY, Peng FK, Chi CW. Helicobacter pylori infection in patients with gastric adenocarcinoma. Tumori 1996;82:40-44.

31. Hansson LE, Engstrand L, Nyren O, Lindgren A. Prevalence of helicobacter-pylori infection in subtypes of gastric-cancer. Gastroenterology 1995;109:885-888.

32. Hu PJ, Li YY, Zhou MH, Chen MH, Du GG, Huang BJ, Mitchell HM, Hazell SL. Helicobacter-pylori-associated with a high prevalence of duodenal-ulcer disease and a low-prevalence of gastric-cancer in a developing-nation. Gut 1995;36:198-202.

33. Klimpfinger M. Therapeutic relevance of the histological gastritis classification. Wiener Klinische Wochenschrift 1994;106:550-555.

E2- O.Çelen, M.J.O'Brien, J.C.Melby, R.M.Beazley. Factors Influencing Outcome of Surgery for Primary Aldosteronism. Archives of Surgery 1996;131:646-650.

1. Y Fujii, Y Takeda, I Kurihara, H Itoh, et al. Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan. Journal of human hypertension. 2020;34:34-42.

2. WF Young Jr.  Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. Journal of internal medicine, 2019;285(2):126-148.

3. - LAP Vilela, M Rassi-Cruz, AG Guimaraes, et al.  KCNJ5 Somatic Mutation Is a Predictor of Hypertension Remission After Adrenalectomy for Unilateral Primary Aldosteronism. The Journal of Clinical Endocrinology and metabolism 2019;104(10):4696-4702.

4. 3- KW Liang, Y Jahangiri, TF Tsao , et al. Effectiveness of thermal ablation for aldosterone-producing adrenal adenoma: a systematic review and meta-analysis of clinical and biochemical parameters. Journal of Vascular and Interventional Radiology 2019;30(9):1335-1342.

5. N Yozamp, A Vaidya . The Prevalence of Primary Aldosteronism and Evolving Approaches for Treatment. Current Opinion in Endocrine and Metabolic  Research 2019;8:30-39.

6. MH Wu, FH Liu, KJ Lin, JH Sun, et al. Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan. Nuclear medicine Communications, 2019;40(6):568-575.

7. A Vaidya, P Mulatero, R Baudrand, et al.  The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocrine Reviews 2018;39(6):1057-1088.

8. SM Dick, M Queiroz, BL Bernardi, et al. Update in diagnosis and management of primary aldosteronism. Clinical Chemistry and Laboratory Medicine  2018;56(3):360-372.

9. WF Young. Diagnosis and management of primary aldosteronism. Adrenal Disorders, 2018;pp245-260.

10. G Jaffe, G Krishnan, M Stedman, Y Zheng, et al. Screening for Primary Aldosteronism in Resistant Hypertension. Available at SSRN …, 2018 - papers.ssrn.com

11. P Sapermsup, N Wongwattanasatien. Factors associated with the normalization of blood pressure after unilateral adrenalectomy for primary hyperaldosteronism patients in Rajavithi Hospital. The Thai Journal of Urology, 2018;39(1):17-25.

12. K Nanba, H Shibata, WE Rainey. Primary Aldosteronism: From Genetic Causes to Clinical Guidelines. Adrenal Disorders, 2018:pp129-146.

13. K Jenwitheesuk, K Jenwitheesuk, S Punchai, et al. What factors impact the treatment outcomes of laparoscopic adrenalectomy in patients with functioning adrenal gland tumors? International Journal of Surgery Open, 2018;14:1-5.

14. RN Srinivasa, ME Anderson, AP Dackiw et al. Combined Efficacy of Adrenal Vein Sampling and Imaging Findings in Predicting Clinical Outcomes Following Unilateral Adrenalectomy for Primary Aldosteronism.  Journal of Clinical Interventional Radiology 2017;01(02):71-76.

15. WF Young Jr, DA Calhoun, JWM Lenders, et al. Screening for endocrine hypertension: an endocrine society scientific statement. Endocrine Reviews, 2017;38(2):103-122.

16. LAP Vilela, MQ Almeida. Diagnosis and management of primary aldosteronism. Archives of endocrinology and metabolism, 2017;61(3):305-312.

17. JW Funder, RM Carey, F Mantero et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism  2016;101:1889-1916. 

18. SC Käyser, T Dekkers, HJ Groenewoud et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis The Journal of Clinical Endocrinology and Metabolism  2016;101:2826-2835. 

19. M Stowasser, RD Gordon. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney Physiological reviews, 2016;96(4):1327-1384.

20. A Vaidya, R Dluhy. Hyperaldosteronism.  Endotext [Internet], 2016 - ncbi.nlm.nih.gov

21. SYW Liu, CCM Chu, TKC Tsui, et al. Aldosterone-producing Adenoma in Primary Aldosteronism: CT-guided Radiofrequency Ablation—Long-term Results and Recurrence Rate. Radiology, 2016;281(2):625-634. 

22. SY Liu, CM Chu, AP Kong, SK Wong Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone‐producing adenoma. British Journal of Surgery 2016;103(11):1476-1486.

23. JI Lee, SC Oltmann, SL Woodruff, et al. Contralateral adrenal abnormalities in Conn's syndrome.  journal of surgical Research  2016;200;183-188.

24. A Łebek-Szatańska, L Papierska Hormonal testing for primary aldosteronism–new guidelines, old problems. Postępy Nauk Medycznych, 2016;XXIX(12):915-920.

25. M Rehan, JE Raizman, E Cavalier et al. Laboratory challenges in primary aldosteronism screening and diagnosis. Clinical Biochemistry, 2015;48(6): 377-385.

26. N Martell-Claros, MÃ Abad-Cardiel et al.  Primary aldosteronism and its various clinical scenarios.  Journal of Hypertension,  2015;33(6): 1226-1232. 

27. M Stowasser -Adrenal venous sampling for differentiating unilateral from bilateral primary aldosteronism: Still the best, but could be better. Hypertension 2015;65(4): 704-706. 

28. B Yao, Z Qin, Y Tan, Y He, J Yan, Q Liang et al.  Rhabdomyolysis in Primary Aldosteronism: A Case Report and Review of the Literature. ACE Clinical Case Reports 2015;1:21-27.

29. KP Economopoulos, CC Lubitz . Primary Aldosteronism. Surgical Endocrinopathies, 2015;203-210. 

30.  Rehan M, Raizman JE, Cavalier E, Et al. Laboratory challenges in primary aldosteronism screening and diagnosis. Clinical Biochemistry 2015;48(6)377-387.

31. SH Ahmed, DL Ewins, S Nair, et al. Spontaneous hypokalaemia in a man with treated hypertension  Bmj, 2015;350:2154-.

32.  SJ Galati, AC Levine - Primary Aldosteronism A Case-Based Guide to Clinical Endocrinology, 2015 ;pp187-198.) 

33. S Monticone, F Satoh, A Viola, E Fischer  et al. Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. The Journal of Clinical Endocrinology & Metabolism, 2014;99(11), 4158–4166.

34. H Wachtel, I Cerullo, EK Bartlett, RR Kelz, et al.  Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism Surgery, 2014;156(6), 1394-1403

35. SE Park, NS Lee, JW Park  et al. Association of urinary RBP4 with insulin resistance, inflammation, and microalbuminuria.  European Journal of Endocrinology,  2014;171;443-449.

36. Fingeret AL, Lee JA. Adrenal Venous Sampling in Primary Hyperaldosteronism. Current Surgery Reports 2014;2:238.

37. Kim SH, Ahn JE, Hong CE, et al.  Changes in the clinical manifestations of primary aldosteronism. The Korean Journal of Internal Medicine 2014;29(2):217-225.

38. M Stowasser - Aldosterone excess and resistant hypertension: investigation and treatment Current hypertension reports, 2014;16: 439-.

39. AL Shada, JB Stokes, FE Turrentine et al.  Adrenalectomy for adrenal-mediated hypertension: national surgical quality improvement program analysis of an institutional experience. The American Surgeon  2014; 80(11): 1152-1158.

40. Viola A, Tizzani D, Monticone S, et al. Diagnosis and treatment of unilateral forms of primary aldosteronism. Curr Hypertens Rev. 2013 May;9(2):156-65.

41. Stowasser M, Gordon RD.The renaissance of primary aldosteronism: what has it taught us? Heart Lung Circ. 2013 Jun;22(6):412-20.

42. Weisbrod AB, Webb RC, Mathur A, Et al. Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism. Ann Surg Oncol 2013 Mar;20(3):753-8

43. Uribarrena-Amezaga R,  Ortego J, Fuentes J et al.  Prognostic value of lymph node micrometastasis in patients with colorectal cancer in Dukes stages A and B (T1-T4, N0, M0). Revista Espanola de Enfermedades Digestivas : Organo Oficial de la Sociedad Espanola de Patologia Digestiva 2010, 102(3):176-186.

44. Uribarrena-Amezaga R,  Ortego J, Fuentes J et al. Prognostic Value of Microvascular Density in Dukes A and B (T1–T4, N0, M0) Colorectal Carcinoma. Gastroenterology Research and Practice. 2009; Article ID 679830, 7 pages, http://dx.doi.org/10.1155/2009/679830

45. Mazza A, Armigliato M, Zamboni S, et al. Endocrine arterial hypertension: therapeutic approach in clinical practice. Minerva Endocrinologica  2008;33(4):297-312.

46. Karagiannis A, Tziomalos K, Kakafika AI, et al. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas
    Endocrine-Related Cancer   2008;15(3):693-700.

47. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2008;93(9):3266-3281.

48. Mourad JJ, Girerd X, Milliez P, et al. Urinary aldosterone-to-active-renin ratio: A useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. American Journal of Hypertension   2008;21(7):742-747.

49. Walz MK, Gwosdz R, Levin SL, et al. Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World Journal of Surgery   2008;32(5):847-853.

1. Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008;51(5).1366-1371.

2. Zarnegar R, Young WF, Lee J, et al. The aldosteronoma resolution score - Predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Annals of Surgery   2008;247(3):511-518.

3. Zarnegar R, Lee J, Brunaud L, et al. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma. Surgery 2007;142(6):921-928.

4. Gordon RD, Stowasser M. Primary aldosteronism: the case for screening
   Nature Clinical Practice Nephrology  2007;3(11):582-583.

5. Lau JHG, Drake W, Matson M. The current role of venous sampling in the localization of endocrine disease Cardiovascular and Interventional Radiology  2007;30(4):555-570. 

6. Pang TC, Bambach C, Monaghan JC, et al. Outcomes of laparoscopic adrenalectomy for hyperladosteronism ANZ Journal Of Surgery  2007;77(9):768-773.

7. Novello M, Catena C, Nadalini E, et al. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment Journal of Hypertension  2007;25(7):1443-1450. 

8. Catena C, Colussi G, Nadahni E, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism Clinical Journal of The American Society of Nephrology 2007;2(4)722-731. 

9. Vesin C, Chabre O, Mallion JM, et al. Diagnosis and post-operative evolution of patients operated for adrenal adenoma (Conn syndrome). A 12-years retrospective study. Archives Des Maladies Du Coeur Et Des Vaisseaux 2007;100(2)121-125.

10. Young WF. Primary aldosteronism: renaissance of a syndrome Clinical Endocrinology 2007;66(5):607-618.

11. Gockel I, Heintz A, Polta M, et al. Long-term results of endoscopic adrenalectomy for Conn's syndrome American Surgeon 2007;73(2)174-180.

12. [Anon] Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004) Hypertension Research 2006;29(Suppl. S):S1-+. 

13. Tan YY, Ogilvie JB, Triponez F, et al. Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World Journal of Surgery 2006;30(5):879-885.

14. Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism - Effect of adrenal vein sampling on surgical outcome. Archives of Surgery 2006;141(5)497-502. 

15. Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nature Clinical Practice Nephrology 2006;2(4):198-208. 

16. Novitsky YW, Kercher KW, Rosen MJ, et al.Clinical outcomes of laparoscopic adrenelectomy for lateralizing nodular hyperplasia. Surgery 2005;138(6):1009-1016.

17. Lumachi F, Ermani M, Basso SMM, et al. Long-term results of adrenelectomy in patients with aldosterone-producing adenomas: Multivariate analysis of factors affecting unresolved hypertension and review of the literature. American Surgeon 2005;71(10):864-869.

18. Ogilvie JB, Duh GY. New approaches to the minimally invasive treatment of adrenal lesions. Cancer Journal 2005;11(1):64-72.

19. Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenelectomy for primary aldosteronism. World Journal of Surgery 2005;29(2):155-159.

20. Stowasser M, Gordon RD. The aldosteron-renin ratioin screening for primary aldosteronism. Endocrinologist 2004;14(5):267-276.

21. Al Fehaily M, Duh GY. Clinical manifestation of aldesteronoma. Surgical Clinics of North America 2004;84(3):887-.

22. Stowasser M, Gordon RD. Primary aldosteronism- careful investigation is essential and rewarding. Molecular and Cellular Endocrinology 2004;217(1-2):33-39.

23. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Extensive personal experience – increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism 2004;89:1045-1050. 

24. Stowasser M, Gordon RD. Primary Aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 2003;17:591-605. 

25. Young WF. Primary aldosteronism- treatment options. Growth Hormone & IGF Research 2003;13(Suppl.A):S102-S108.

26. Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics. Trends in Endocrinology and Metabolism 2003;14:310-317.

27. Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG, Delbridge LW. Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ Journal of Surgery 2003;73:727-738.

28. Wheeler MH, Harris DA. Diagnosis and management of primary aldosteronism. World Journal of Surgery 2003;27:627-631.

29.  Harris DA, Au-Yong I,  Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. European Journal of Surgical Oncology 2003;29:467-474.

30. Lumachi F, Marzola MC, Zucchetta P, Tregnaghi A, Cecchin D, Favia G, Bui F. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nuclear Medicine Communications 2003;24:683-688.

31. Young WF. Minireview: Primary aldosteronism – Changing concepts in diagnosis and treatment. Endocrinology 2003;144:2208-2213.

32. Meria P, Kempf BF, Hermieu JF, Plouin PF,Duclos JM. Laparoscopic management of primary hyperaldosteronism: Clinical experience with 212 cases. Journal of Urology 2003;169(1):32-35.

33. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. British Journal of Surgery 2002;89:1587-1593.

34. Fukudome Y, Fujii K, Arima H, Ohya Y, Tsuchihashi T, Abe I,  Fujishima M. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertension Research 2002;25:11-18.

35. Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. American Surgeon 2002;68:253-256.

36. Brand M, Dehmel B, Cristow S, Kettritz R. A strange case of hypokalaemia. Nephrology Dialysis Transplantation 2002;17:297-299.

37. Brunt LM, Moley JF, Doherty DM, Lairmore TC, DeBenedetti MK, Quasebarth MA. Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors. Surgery 2001;130:629-634.

38. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Annals of Internal Medicine 2001;135:258-261.

39. Horita Y, Inenaga T, Nakahama H, Ishibashi-Ueda H, Kawano Y,  Nakamura S, Horio T, Okuda N, Ando M, Takishita S. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. American Journal of Kidney Diseases 2001;37:884-889.

40. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. Journal of Hypertension 2001;19:353-361.

41. Nocaudie-Calzada M, Huglo D, Lambert M, Ernst O, Proye C, Werneau JL, Marchandise X. Efficacy of iodine-131 6 beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism. European Journal of Nuclear Medicine 1999;26:1326-1332.

42. Flood SM, Randolph JF, Gelzer ARM, Refsal K. Primary hyperaldosteronism in two cats. Journal of the American Animal Hospital Association 1999;35:411-146.

43. Winship SM, Winstanley JHR, Hunter JM. Anaesthesia for Conn's syndrome. Anaesthesia 1999;54:569-574.

44. Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK,  Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Archives of Surgery 1999;134:628-631.

45. Blumenfeld JD, Vaughan ED. Diagnosis and treatment of primary aldosteronism. World Journal of Urology 1999;17:15-21.

46. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T,  Kimura G. Cardiovascular complications in patients with primary aldosteronism. American Journal of Kidney Diseases 1999;33:261-266.

47. Proye CAG, Mulliez EAR, Carnaille BML, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998;124:1128-1133.

48. Fahmy HI, Melby JC, Mesler DE, Beazley RM, Cho SI, Idelson BA. Primary hyperaldosteronism causing posttransplantation hypertension: Localization by adrenal vein sampling. American Journal of Kidney Diseases 1998;31:853-855.

49. Siren J, Valimaki M, Huikuri K, Sivula A, Voutilainen P, Haapiainen R. Adrenalectomy for primary aldosteronism: Long-term follow-up study in 29 patients. World Journal of Surgery 1998;22:418-422.

50. Young WF. Pheochromocytoma and primary aldosteronism: Diagnostic approaches. Endocrinology and Metabolism Clinics of North America 1997;26:801.

51. Young WF. Primary aldosteronism: Update on diagnosis and treatment. Endocrinologist 1997;7:213-221.

E3- E.Yıldırım, O.Çelen, U.Berberoğlu. The Turkish experience with curative gastrectomies for gastric carcinoma: Is D2 dissection worthwhile? Journal of the American College of Surgeons 2001,192:25-37.

1. M Kalbasi, S Siadati, S Kamali Ahangar, et al. Clinicopathologic Characteristics of Multifocal Gastric Adenocarcinoma. Journal of Babol University of Medical Science.  2019;21(1)147-152.
2. M Moehler, T Langer, T Bender, J Kofent , et al. Leitlinienreport zur S3-Leitlinie Magenkarzinom–„Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs “. Zeitschrift für Gastroenterologicie 2019 ;57(12):418-671. 
3. H Darwish, A Sakr, W Basaam, A Ghorab. 10 years Experience in the Treatment of Gastric Cancer: A Single Egyptian Cancer Center (NEMROCK). Pan Arab Journal of Oncology 2016;9(3):35-41.
4.  TAH El-Fayoumi, HM Fyed, ME Mesiry et al. The applicability of D2 gastrectomy in operable gastric cancer patients: A trial of Alexandria Surgical Oncology Unit Alexandria J Medicine 2013; 49(3):229-234.
5. WH Allum, JM Blazeby, SM Griffin, D Cunningham et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011;60: 1449-1472.
6. MA Memon, MS Subramanya, S Khan et al. Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric Adenocarcinoma Annals of Surgery 2011;253(5):900-911.
7. M Scatizzi, KC Kröning, E Lenzi et al. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case–control study. Updates in Surgery 2011;63: 17-23.
8. SS Yoon, HK Yang.  Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East? The oncologist 2009;14:871-882.
9. H Derici, I Yaman, T Tansug, O Nazli, et al. Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Research 2009;2(6):317-323.
10. S Yalcin. Gastric Cancer in Turkey—A Bridge Between West and East. Gastrointestinal cancer research 2009;3(1):29-32.
11. Ozmen MM, Ozmen F, Zulfikaroglu. Lymph Nodes in Gastric Cancer
    Journal of Surgical Oncology 2008;98(6):476-481.
12. Leong CN, Chung HT, Lee KM, et al. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer Journal 2008;14:269-275.
13. Park JM, Kim JH, Park SS, et al. Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: Comparative analysis of subgroups in stage II. World Journal of Surgery 2008;32:1037-1044.
14. Sasagawa T, Solano H, Vega W, Mena F. The effectiveness of extended lymph node dissection for gastric cancer performed in Costa Rica under supervision of a Japanese surgeon: A comparison with surgical results in Japan. American Journal of Surgery 2008;195:53-60.
15. Kim MC, Jung GJ, Kim HH.Morbidity and mortality of laparoscopy-assisted gastrectomy with extraperigastric lymph node dissection for gastric cancer.Digestive Diseases And Sciences 2007;52: 543-548.
16. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. European Urology 2007;52: 29-37, 
17. Huscher CGS, Mingoli A, Sgarzini G, et al.Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early long-term results and advanced gastric cancer: early and of a 100-patient series. American Journal of Surgery 2007;194: 839-844.
18. Wyler SF, Sulser T, Seifert HH, et al. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 2006;68:883-887,
19. Burkhard FC, Schumaher M, Thalman GN, Studer UE. Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of < 10 ng/ml undergoing radical prostatectomy for prostate cancer? BJU International 2005;95(3)275-278.
20. Torres JE, Tsoulfas G, Hamdy K, Scott-Conner CEH. Laparoscopic surgery for the prevention, palliation and cure of gastrointestinal malignancies. Medical Clinics of North America 2005;89(1):187-.
21. Huscher CG, Mingoli A, Sgarzini G, et al. Videolaparoscopic total and subtotal gastrectomy with extended lymph node dissection for gastric cancer. American Journal of Surgery 2004;188(6):728-733.
22. Shimoyama S, Mafune K, Kaminishi M. Indications for a pylorus-preseving gastrectomy for gastric cancer with proper muscle invasion. Archives of Surgery 2003;138:1235-1239.
23. Bostancı EB, Yol S, Kayaalp C, Özoğul Y, Atdın C, Atalay F, Akoğlu M. Comparison of complications after D2 and D3 dissection for gastric cancer. European Journal of Surgical Oncology 2004,30:20-25.
24. Bass BL.What's new in general surgery: Gastrointestinal conditions. Journal of the American College of Surgeons 2002;195:835-54.
25. Kasakura Y, Mochizuki F, Wakabayashi K, Kochi M, Fujii M, Takayama T. An evaluation of the effectiveness of extended lymph node dissection in patients with gastric cancer: A retrospective study of 1403 cases at a single institution. Journal of Surgical Research 2002;103:252-259.
26. Spanknebel KA, Brennan MF. Is D2 lymphadenectomy for gastric cancer a staging tool or a therapeutic intervention? Surgical Oncology Clinics Of North America 2002;11:415-430.

E4- H.Altınyollar, U.Berberoğlu, O.Çelen. Lymphatic mapping and sentinel lymph node biopsy in squamous cell carcinoma of the lower lip. European Journal of Surgical Oncology 2002;28:72-74.

1. NK Kavabata, DN Caly, TH Ching, et al. Predictive factors for late cervical metastasis in stage I and II squamous cell carcinoma of the lip. European Archives of Oto-Rhino-Laryngology, 2019;276(7):2047-2053.
2. CP Mooney, RCW Martin, R Dirven, BG Ashford, et al.  Sentinel Node Biopsy in 105 High-Risk Cutaneous SCCs of the Head and Neck: Results of a Multicenter Prospective Study. Annals of surgical oncology, 2019;26(13):4481-4488.
3. M Fox, M Brown, N Golda, D Goldberg, et al.  Nodal staging of high-risk cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019;81(2):548-557. 
4. A Tejera‐Vaquerizo, I García‐Doval, et al. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. The Journal of Dermatology, 2018;45(7):781-790. 
5. D Samsanavicius, V Kaikaris, A Cepas, et al. Importance of sentinel lymphatic node biopsy in detection of early micrometastases in patients with cutaneous squamous cell carcinoma. Journal of Plastic, Reconstructiveand Aesthetic Surgery,  2018;71(4):597-603.
6.  DF Contreras Pérez, JP Molina Jiménez , et al. Skin Squamous Cell Carcinoma of the trunk and limbs: Role of Sentinel Node Biopsy in its staging. Revista Colombiana de Cancerologia, 2018;22(1):39-45.
7. SE Díaz, JP Molina, DF Contreras, D López, et al. Sentinel Node in Cutaneous Squamous Cell Carcinoma of the Trunk and Extremities: Experience in a Latin American Reference Center. Journal of Cancer  Therapy, 2018;9(2):130-144.
8. O Ahadiat, S Higgins, A Sutton, et al. SLNB in cutaneous SCC: A review of the current state of literature and the direction for the future. Journal of surgical oncology, 2017;116(3):344-350.
9. R Kollipara, E Shane, S Shah, SK Tyring Iatrogenic Immunodeficiency and Skin Disease. Clinical and Basic Immunodermatology 2017:685-694. Springer
10. SM Gore, D Shaw, RCW Martin, et al. Prospective study of sentinel node biopsy for high‐risk cutaneous squamous cell carcinoma of the head and neck. Head & Neck, 2016;38(51):884-889
11. EMJ Sollamo, SK Ilmonen, MS Virolainen, et al. Sentinel lymph node biopsy in cN0 squamous cell carcinoma of the lip: A retrospective study.  Head & Neck 2016;38(51):1375-1380. 
12. SY Kang, AE Toland .High risk cutaneous squamous cell carcinoma of the head and neck. World journal of otorhinolaryngology-head and neck surgery, 2016;2(2):136-140.
13. SS Sirvan, I Akgun, KZ Sevim, et al. Sentinel lymph node biopsy for skin tumors. Sisli Etfal Tıp Bülteni, 2016;50(3):220-227.
14. C Navarrete-Dechent, MJ Veness High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: a literature review.  Journal of the American Academy of Dermatology 2015;73(1):127-137.
15. JE Allen, LB Stolle Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. European Journal of Surgical Oncology (EJSO), 2015;41(2):197-200. 
16. K Wermker, F Belok, S Schipmann, M Klein, et al.  Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. Journal of Cranio-Maxillofascial Surgery 2015;43(4):545-552.
17. E Silberstein, E Sofrin, et al.  . Lymph node metastasis in cutaneous head and neck squamous cell carcinoma. Dermatologic  Surgery 2015;41(10):1126-1129.
18. M Alexiades-Armenakas . Commentary on photodynamic therapy of actinic cheilitis. Dermatologic Surgery, 2015;41(2):199-200.
19. ML Stevenson, JA Carucci.  Advances in management of “high-risk squamous cell carcinoma” in organ transplant recipients. Advances in Transplant Dermatology, 2015;pp87-97. Springer.
20. J Wykes, J Clark, N Niles.  The Role of Sentinel Lymph Node Biopsy in Non-melanoma Skin Cancer of the Head and Neck. Non-melanoma Skin Cancer of the Head and Neck, 2015;pp83-91. Springer
21.   GMD Carvalho, V Gonçalves-Silva Head and Neck Cancer Treatment with Sentinel Node Biopsy without Eletive Neck Dissection. MOJ Clin Med Case Reports 2015;3(2):1-6.
22. C Jameson, G Morgan, CE Palme, et al.  Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck Non-melanoma Skin Cancer of the Head and Neck 2015 :pp93-115- Springer
23. AR Schmitt, JD Brewer, JS Bordeaux   Staging for Cutaneous Squamous Cell Carcinoma as a Predictor of Sentinel Lymph Node Biopsy Results Meta-analysis of American Joint Committee on Cancer Criteria and a Proposed Alternative System  JAMA  Dermatol 2014;150(1):19-24.
24. Guinot JL, Arribas, L, Vendrell JB et al. Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapy Head & Neck 2014;36(12):1737-1742.
25. Allen JE, Stolle LB.  Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma European Journal of Surgical Oncology 2014.
26. G Tanyeri, G Eskiizmir.  The management, current treatment modalities and reconstruction techniques for lip cancer. Turk Arch Otolaryngol, 2014;52:22-31.
27. O Malard, G Michel, F Espitalier.  Chirurgia dei tumori delle labbra. EMC-Tecniche Chirurgiche-Chirurgia ORL e Cervico-Fasciale  2014;18(1):1-15.
28. O Malard, G Michel, F Espitalier Cirugía de los tumores labiales. EMC-Cirugía Otorrinolaringológica y Cervicofascial 2014;15(1):1-14.
29. Bassi, KK, Srivastava A, Seenu V et al. The First and Second Echelon Sentinel Lymph Node Evaluation in Oral Cancer. Indian Journal of Surgery 2013;75: 377-382.
30. Vanderlei JPM,  Pereira-Filho FJF , et al. Management of neck metastases in T2N0 lip squamous cell carcinoma. American journal of otolaryngology 2013:34(2): 103-106.
31. Spratt EAG, Carucci JA. Skin Cancer in Immunosuppressed Patients. Facial Plastic Surgery 2013;29: 402-410.
32. Gutiérrez‐Pascual, M., et al. Squamous cell carcinoma of the lip. A retrospective study of 146 patients. Journal of the European Academy of Dermatology and Venereology 2012;16(9):1116-1121.
33. Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatologic clinics 2011;29(2): 231-241.
34. Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J Surg Oncol  2011;9: 80.
35.  D Belkin, JA Carucci. Carucci. Mohs surgery for squamous cell carcinoma. Dermatologic clinics 2011;29(2): 161-174.
36.  Guibert M, David I, Vergez  S et al. Brachytherapy in lip carcinoma: long-term results. International Journal of Radiation Oncology* Biology* Physics  2011;81(5): e839-e843.
37.  Xiqiang L, Kolokythas A, Wang J et al. Gene expression signatures of lymph node metastasis in oral cancer: molecular characteristics and clinical significances. Current cancer therapy reviews 2010;6(4): 294.
38.  MA Kuriakose, NP Trivedi. Sentinel node biopsy in head and neck squamous cell carcinoma. Current opinion in otolaryngology & head and neck surgery 2009;17(2): 100-110.
39.  Sarper Y, and Ercocen AR. Is Elective Neck Dissection in T1–2, N0 Patients With Lower Lip Cancer Necessary?. Annals of plastic surgery 2009;62: 381-383.
40. Civantos F, Zitsch R, Bared A, et al. Sentinel node biopsy for squamous cell carcinoma of the head and neck. Journal of Surgical Oncology 2008;97(8):683-690.
41.  Reichrath J, Nurnberg. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Sunlight, Vitamin D and Skin Cancer  Book Series: Advances in Experimental Medicine and Biology 2008;624:203-214.
42. Morselli P, Masciotra L, Pinto V, et al. Clinical parameters in T1NOMO lower lip squamous cell carcinoma. Journal of Craniofacial Surgery 2007;18(5):1079-1082. 
43. Civantos F, Zitsch R, Bared A. Sentinel node biopsy in oral squamous cell carcinoma. Journal of Surgical Oncology 2007;96(4)330-336. 
44. Renzi C, Caggiati A, Mannooranparampil TJ, et al. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature EJSO 2007;33(3):364-369. 
45. Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: Is there a therapeutic role for elective neck dissection? Dermatologıc Surgery 2007;33(4):410-420. 
46. Devaney KO, Rinaldo A, Rodrigo JP, et al. Sentinel node biopsy and head and neck tumors - Where do we stand today? Head and Neck-Journal for The Sciences And Specialties of The Head and Neck 2006;28(12):1122-1131. 
47. Ross AS, Schmults CD.Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: A systematic review of the English literature. Dermatologic Surgery  2006;32(11):1309-1321.
48. Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: Contrasts between oral cavity and cutaneous malignancy Laryngoscope  2006;116(3):1-15
49. Cecchi R, Buralli L, De Gaudio C. Lymphatic mapping and sentinel lymphadenectomy in recurrent cutaneous squamous cell carcinomas. European Journal of Dermatology 2005;15(6):478-479.
50. Paleri V, Rees G, Arullenoran P, et al. sentinel lymph node biopsy in squamous cell carcinoma in squamous cell cancer of the oral cavity and oral pharynx: A diagnostic meta-analysis. Head and Neck Journal for the Sciences Specialties of the Head and Neck 2005;27(9):739-747.
51. Somma P, Lo Muzio L, Mansueto G, et al. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. International Journal of Immunopathology and Pharmacology 2005;18(1):59-64.
52. Nouri K, Rivas MP, Pedroso F, et al. Sentinel lymph node biopsy for high risk squamous cell carcinoma of the head and neck. Archives of Dermathology 2004;140(10):1284-1284.
53. Carucci JA. Cutaneous oncology in organ transplant recipients: Meeting the challenge of squamous cell carcinoma. Journal of Investigative Dermatology 2004;123(5):809-816.
54. Stasko T, Brown MD, Carucci JA, Euvrard S, Johnson TM,Sengelmann RD, Stockfleth E, Tope WD. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatologic Surgery 2004, 30:642-650.
55. Vartanian JG, Carvalho AL, de Arajo MJ, Hattori M, Magrin J, Kowalski LP. Predictive factors and distribution of lymph node metastasis in lip cancer patients and their implications on the treatment of the neck. Oral Surgery 2004;40:223-227.
56. Carucci JA. Management of squamous cell carcinoma in organ transplant recipients. Seminars in Cutaneous Medicine and Surgery 2003;22:177-186.
57. Blazer DG, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surgical Oncology-Oxford 2003;12:201-206.
58. Pitman KT, Ferlito A, Devaney KO, Shaha AR, Rinaldo A. Sentinel lymph node biopsy in head and neck cancer. Oral Oncology 2003;39:343-349.